New York, New York--(Newsfile Corp. - August 5, 2024) - Quantum Research Group, LLC published the results of a new survey entitled "Investor Insights into Psychedelic Stocks." According to the data gathered in April 2024, 66 percent of investors are psychedelic friendly, but only 6 percent are invested in one or more psychedelic stocks.
Psychedelic-friendly investors include those who either have already invested in psychedelic stocks or those considering investing in them in the future. The survey also found that two-thirds of investors interested in psychedelic stocks are planning to increase their investments in the space over the next year.
"The psychedelic market was estimated to be worth $2.7 billion in 2024 and is expected to surpass $7.35 billion by 2031," said Ari Zoldan, CEO of Quantum.
The strongest draw for psychedelic-friendly investors to stocks in the space is the growth potential, with 73 percent citing this factor as their top reason for interest in the space. In second place came the expected potential for high financial returns on psychedelic stocks, at 70 percent of investors.
Sixty-seven percent of psychedelic-friendly investors believe advancements in psychedelic research will positively impact the pharmaceutical industry as a whole. Meanwhile, 57 percent are optimistic about potential market or sales growth in the psychedelic sector.
"The only way to build patient, provider, payer and investor confidence in the potential of psychedelics is to devote substantial resources to studying and reporting on its safety and efficacy," said Joel Latham, president and CEO of Incannex. "There remains tremendous unmet treatment needs in mental health, which is why we are committed to advancing our psilocybin research program towards commercialization in the United States and beyond."
The complete data is available here via Quantum Research Group's website.
About Quantum Research Group, LLC
Quantum Research Group, LLC is a global consultancy firm that integrates investor relations, public relations, and equity research into a unique hybrid approach to deliver measurable results to publicly traded companies on the NASDAQ, NYSE, and AMEX stock exchanges. Their distribution partners include dozens of leading financial platforms.
Disclosures
Quantum Research Group, LLC is being compensated by Incannex for providing media coverage and research materials regarding them and their securities. Investors can find company-specific and/ or macro-related risk factors in the respective financial filings of Incannex.
Statements within this report may constitute forward-looking statements involving many uncertainties and risk factors around the named businesses, industry, and macroeconomic environment. All data covered in this report is based on a survey conducted by Quantum Research Group, LLC on behalf of Incannex in April 2024, and no investment recommendations are made within the resulting report on that survey or this press release.
This report and press release do not take into account individual investor circumstances or preferences. Investors must do their due diligence and be aware of the high degree of risk in biotechnology stocks and small-cap equities, including the potential for a complete loss of their investment.
Quantum Research Group, LLC may be compensated for non-research-related services, including issuing press releases and securing media coverage, writing articles, and providing investor relations services and other additional services. The costs associated with non-research-related services are dependent on the terms of the contract with each individual company. Issuers are not required to engage us for these additional services.
Quantum Research Group's research is based on publicly available information and no investment recommendations are made within this report.
CONTACT:
Jessica Daitch
jessica@quantum-corp.com
https://www.quantum-corp.com/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218432
SOURCE: Quantum Media Group, LLC
